Literature DB >> 33662279

Undruggable KRAS-time to rebrand?

.   

Abstract

Entities:  

Year:  2021        PMID： 33662279     DOI： 10.1016/S1470-2045(21)00091-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.

Authors:  Chi-Yuan Cheng; Chiao-Ping Chen; Chiao-En Wu
Journal:  Life (Basel)       Date:  2022-06-02

2.  FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.

Authors:  Erica C Nakajima; Nicole Drezner; Xiaoxue Li; Pallavi S Mishra-Kalyani; Yajun Liu; Hong Zhao; Youwei Bi; Jiang Liu; Atiqur Rahman; Emily Wearne; Idara Ojofeitimi; Lauren Tesh Hotaki; Dianne Spillman; Richard Pazdur; Julia A Beaver; Harpreet Singh
Journal:  Clin Cancer Res       Date:  2022-04-14       Impact factor: 13.801

Review 3.  Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling.

Authors:  Aoife A Nolan; Nourhan K Aboud; Walter Kolch; David Matallanas
Journal:  Genes (Basel)       Date:  2021-04-10       Impact factor: 4.096
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.